Health at a Glance Report highlights public value of generic, biosimilar and value added medicines

26 November 2018

The European Commission and OECD – Health at a Glance: […]

Value added medicines: Continuous innovation crucial to improve healthcare across Europe

21 November 2018

The 2nd Value Added Medicines conference gathered a wide range […]

Driving local excellence, delivering European results

5 November 2018

Medicines for Europe is glad to announce the occasion of […]

US interference unacceptable in EU legislative proposal for an SPC manufacturing waiver

22 October 2018

The US patent and trademark office (USPTO), together with the […]

Risk that European Council will “neuter” SPC manufacturing waiver and give foreign (non-EU) manufacturers strong advantage over EU-based manufacturers

11 October 2018

There is a concrete risk that disproportionate influence on the […]

CJEU decision on Gilead’s SPC on Truvada® leads to successful clarification in English court

20 September 2018

An English Court has determined that the contested supplementary protection […]

SPC manufacturing waiver is good news for Europe

19 September 2018

An SPC manufacturing waiver should be extremely beneficial for Europe […]

SPC manufacturing waiver moves a step closer as influential European Parliament ENVI Committee supports reform

17 September 2018

Medicines for Europe welcomes the European Parliament’s Committee on Environment, […]

Multi-stakeholder workshop on biosimilar medicines a crucial milestone in achieving increased patient access to biological therapies

14 September 2018

Analysis of the proposal for a regulation of a manufacturing exception related to the SPC and aimed to make the European industry competitive

13 September 2018